Discontinued — last reported Q3 '16
Abbott Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) decreased by 39.5% to $363.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 40.0%, from $605.00M to $363.00M. Over 3 years (FY 2022 to FY 2025), Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) shows a downward trend with a -32.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Higher values indicate a larger near-term drag on reported earnings due to previous acquisition activity.
This represents the projected non-cash expense related to the amortization of finite-lived intangible assets for the upc...
Companies with high M&A activity in the medical device space typically report significant annual amortization expenses.
finite_lived_intangible_assets_amortization_year_1| Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.60B | $1.60B | $1.20B | $1.20B | $1.30B | $1.30B | $700.00M | $700.00M | $700.00M | $700.00M | $605.00M | $600.00M | $600.00M | $600.00M | $363.00M |
| QoQ Change | — | +0.0% | -25.0% | +0.0% | +8.3% | +0.0% | -46.2% | +0.0% | +0.0% | +0.0% | -13.6% | -0.8% | +0.0% | +0.0% | -39.5% |
| YoY Change | — | — | — | — | -18.8% | -18.8% | -41.7% | -41.7% | -46.2% | -46.2% | -13.6% | -14.3% | -14.3% | -14.3% | -40.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.